Cargando…
Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
Autores principales: | Mastorino, Luca, Siliquini, Niccolò, Avallone, Gianluca, Ortoncelli, Michela, Quaglino, Pietro, Dapavo, Paolo, Ribero, Simone |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527684/ https://www.ncbi.nlm.nih.gov/pubmed/36199899 http://dx.doi.org/10.4081/dr.2022.9282 |
Ejemplares similares
-
Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real‐life study
por: Mastorino, Luca, et al.
Publicado: (2022) -
Risankizumab shows high efficacy and maintenance in improvement of response until week 52
por: Mastorino, Luca, et al.
Publicado: (2022) -
Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population
por: Mastorino, Luca, et al.
Publicado: (2022) -
Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice?
por: Mastorino, Luca, et al.
Publicado: (2022) -
Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy
por: MASTORINO, Luca, et al.
Publicado: (2022)